Comparison of the Effects of Policosanol and Atorvastatin on Lipid Profile and Platelet Aggregation in Patients with Dyslipidaemia and Type 2 Diabetes Mellitus

Clinical Drug Investigation

Volumn 23, Issue 10, 2003, Pages 639-650

  Castaño, Gladys ^a   Fernández, Lilia ^b   Mas, Rosa ^b   Illnait, José ^b   Mesa, Meylin ^a   Fernandez J C ^b  

^a Medical Surgical Research Center   (Cuba)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ATORVASTATIN; CREATINE KINASE; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLICOSANOL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; INSOMNIA; LIPID COMPOSITION; MALE; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PARALLEL DESIGN; PRIORITY JOURNAL; PRURITUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION;

EID: 0142074299     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323100-00003     Document Type: Article

References (59)

1. World Health Organization. World Health Report 1998: Life in the 21st century: a vision of all. Geneva: World Health Organization, 1998
2. Expert Panel of Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
3. Gotto AM, Assman G, Carmena R, et al. The ILIB lipid handbook for clinical practice: blood lipids and coronary heart disease. 2nd ed. New York: International Lipid Information Bureau (ILIB), 2000
4. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: I. Reduction in the incidence of coronary heart disease. JAMA 1984; 251: 351-64
5. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: II. The relationship of reduction in the incidence of coronary heart disease to cholesterol-lowering. JAMA 1984; 251: 365-74
6. Frick MH, Elo O, Happa K, et al. Helsinki Heart Study: primary-prevention with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-45
7. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
8. Sacks FM, Pfeffer MA, Moy LA, et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
9. Tonkin A, Aylward P, Colqhoun D, et al. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
10. Shepherd S, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
11. Downs JR, Clearfield M, Weiss S, et al. for the AFCAPS/ TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22
12. Heart Protection Study Collaborative Group. MRC/BFH Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
13. Laakso M. Epidemiology of diabetic dyslipidemia. Diabetes Rev 1995; 3: 408-22
14. Sasaki A, Uehara M, Horiuchi N, et al. A 15 year old follow-up study of patients with non-insulin dependent diabetes mellitus (NIDDM) in Osaka, Japan: long-term prognosis and causes of death. Diabetes Res Clin Pract 1996; 34: 47-55
15. Lee WL, Cheung AM, Cape D, et al. Impact of diabetes on coronary artery disease in women and men: a meta analysis of prospective studies. Diabetes Care 2000; 23: 962-8
16. Haller H. Endothelial function: general considerations. Drugs 1997; 53 Suppl. 1: 1-10
17. Luscher TF, Barton M. Biology of the endothelium. Clin Cardiol 1997; 20 Suppl. II: II2-II10
18. American Diabetes Association. Aspirin in diabetes. Diabetes Care 2002; 25 Suppl. 1: S78-9
19. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Reports of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2002; 25 Suppl. 1: S3-S24
20. Betheridge J. Diabetic dyslipidemia. Am J Med 1994; 96 (6): 25S-30S
21. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998; 21: 160-78
22. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2002; 25 Suppl 1: S74-7
23. Packard C, Caslake M, Shepeherd J. The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol 2000; 74 Suppl. 1: 17S-22S
24. Hunt JV, Dean RT, Wolff SP. Oxidative glycation and free radical production: a causal mechanism of diabetic complication. Free Radic Res Commun 1991; 12-13: 115-23
25. Lea AP, McTavish D. Atorvastatin: a review of its pharmacology and therapeutic potential on hyperlipidaemia control. Drugs 1997; 53: 828-47
26. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thrombosis Vasc Biol 1995; 15: 678-82
27. Demir M, Acarturk E, Sasmaz I, et al. Effects of atorvastatin on lipid profile and coagulation parameters. Curr Ther Res 2001; 62: 691-8
28. Jones P, Kafanek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-7
29. Schuster H, Berger J, Luft F. Randomised, double-blind, parallel-group trial of atorvastatin and fluvastatin on plasma lipid levels in patients with untreated hyperlipidaemia. Br J Cardiol 1998; 5: 597-602
30. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997; 80: 39-44
31. Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 1997; 79: 1475-81
32. Athyros VG, Papageorgious AA, Athyrou V, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined dyslipidemia. Diabetes Care 2002; 25: 1198-202
33. Black DM, Bakker-Arkema R, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMGCoA reductase inhibitor. Arch Intern Med 1998; 158: 577-84
34. Mas R. Policosanol. Drugs of the Future 2000; 25: 569-86
35. Canetti M, Morera M, Illnait J, et al. A two years study on the efficacy and tolerability of policosanol in patients with type II. Int J Clin Pharmacol Res 1995; XV: 159-65
36. Más R, Castaño G, Illnait J, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1999; 65: 6-14
37. Castaño G, Más R, Fernández L, et al. Effect of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 2000; 14: 187-95
38. Benítez M, Romero C, Mas R, et al. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia. Curr Ther Res 1997; 58: 859-67
39. Ortensi G, Gladstein H, Valli H, et al. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res 1997; 58: 390-401
40. Castaño G, Más R, Arruzazabala ML, et al. Effects of policosanol, pravastatin on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res 1999; 19: 105-16
41. Fernández JC, Más R, Castaño G, et al. Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolemic women. Clin Invest 2001; 21: 103-13
42. Castaño G, Mas R, Fernández L, et al. Comparison of the efficacy, safety and tolerability of policosanol versus atorvastatin in elderly patients with type II hypercholesterolemia. Drugs Aging 2003; 20: 153-63
43. Mas R, Castaño G, Fernández L, et al. Effects of policosanol in older hypercholesterolemic patients with coronary disease. Clin Drug Invest 2001; 21: 485-97
44. Menéndez R, Fernández I, Del Rio A, et al. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol Res 1994; 27: 199-203
45. Menéndez R, Arruzazabala ML, Más R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein diet. Br J Nutr 1996; 77: 923-32
46. Menéndez R, Amor A, Rodeiro I, et al. Policosanol modulates HMGCoA reductase activity in cultured fibroblasts. Arch Med Res 2001; 32: 8-12
47. Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995; 18: 393-7
48. Crespo N, Alvarez R, Más R, et al. Effect of policosanol on patients with non-insulin-dependent diabetes mellitus (NIDDM) and hypercholesterolemia. Curr Ther Res 1997; 58: 44-51
49. Crespo N, Illnait J, Mas R, et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non insulin dependent diabetes mellitus. Im J Clin Pharmacol Res 1999; 19: 105-16
50. Fernández L, Más R, Illnait J, et al. Policosanol: results of a postmarketing surveillance control on 27 879 cases. Curr Ther Res 1998; 59: 717-22
51. Más R, Rivas P, Izquierdo JE, et al. Pharmacoepidemiologic study of policosanol. Curr Ther Res 1999; 60: 458-67
52. Corsini A, Pazzucconi F, Arnaboldi L, et al. Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol 1998; 31: 773-8
53. Bellosta S, Ferri N, Arnaboldi L, et al. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 2000; 23 Suppl. 2: B72-6
54. Friedewald WT, Levy RI, Friederickson SD. Estimation of the concentration of low-density-lipoprotein cholesterol in plasma without of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
55. Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: ultracentrifugation vs precipitation with sodium phosphotungstat and magnesium chloride. Clin Chem 1981; 27: 838-41
56. Born G. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-30
57. Arruzazabala ML, Más R, Molina V, et al. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients. Int J Tissue React 1998; 20: 119-24
58. Davi G, Catalano I, Averna M, et al. Thromboxane synthesis and platelet function in diabetes mellitus. N Engl J Med 1990; 322: 1769-74
59. Castaño G, Mas R, Fernández L, et al. Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study. Angiology 2003: 54: 25-38